Nervgen Pharma 's Quick Ratio

NGEN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth

In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 0.87 below Nervgen Pharma Corp average.

Within Major Pharmaceutical Preparations industry 323 other companies have achieved higher Quick Ratio than Nervgen Pharma in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 1591.

Explain Quick Ratio?
How much Cash & cash equivalents NGEN�s has?
What are NGEN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NGEN Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024)
Y / Y Current Liabilities Change	57.72 %	-	-	-	-
Y / Y Cash & cash equivalent Change	34.22 %	-	-	-	-
Quick Ratio MRQ	0.87	1.12	1.12	1.12	1.02
NGEN's Total Ranking	# 1591	#	#	#	#
Seq. Current Liabilities Change	22.47 %	0 %	0 %	28.78 %	-
Seq. Cash & cash equivalent Change	-4.79 %	0 %	0 %	40.98 %	-

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 324
Healthcare Sector	# 584
Overall Market	# 1591

Quick Ratio Statistics
High	Average	Low
1.12	1.12	1.12
(Dec 31 2025)

Financial Statements
Nervgen Pharma 's Current Liabilities	$ 19 Millions	Visit NGEN's Balance sheet
Nervgen Pharma 's Cash & cash equivalent	$ 16 Millions	Visit NGEN's Balance sheet
Source of NGEN's Sales		Visit NGEN's Sales by Geography

Cumulative Nervgen Pharma 's Quick Ratio

NGEN's Quick Ratio for the trailling 12 Months

NGEN Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	444.07 %	-	-	-	-
Y / Y Cash & cash equivalent TTM Growth	457.16 %	-	-	-	-
Quick Ratio TTM	1.05	1.1	1.09	1.08	1.02
Total Ranking TTM	#	#	#	#	#
Seq. Current Liabilities TTM Growth	11.87 %	36.02 %	56.29 %	128.78 %	-
Seq. Cash & cash equivalent TTM Growth	6.54 %	36.91 %	58.5 %	140.98 %	-

Quick ratio ranking by company, industry and sector >> Back to NGEN Financial Strength Comparisons >> Go to Compare NGEN Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q4 2025 to $18.51 millions, cumulative Quick Ratio decreased to 1.05 below the Nervgen Pharma Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 323 other companies have achieved higher Quick Ratio than Nervgen Pharma . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 0.

Explain Quick Ratio?
How much Cash & cash equivalents NGEN�s has?
What are NGEN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 324
Healthcare Sector	# 584
Within the Market	# 1591

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.12	1.12	1.12
(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Hyperion Defi inc	2.39	$ 6.443 Millions	$ 2.701 Millions
Nuvectis Pharma inc	2.38	$ 31.634 Millions	$ 13.296 Millions
Seres Therapeutics Inc	2.37	$ 45.766 Millions	$ 19.322 Millions
Satellos Bioscience Inc	2.35	$ 9.804 Millions	$ 4.177 Millions
Insmed Inc	2.31	$ 1,430.047 Millions	$ 618.925 Millions
Actuate Therapeutics Inc	2.31	$ 13.159 Millions	$ 5.707 Millions
Elicio Therapeutics Inc	2.29	$ 18.563 Millions	$ 8.110 Millions
Lantern Pharma Inc	2.29	$ 10.119 Millions	$ 4.423 Millions
Regeneron Pharmaceuticals Inc	2.26	$ 8,605.200 Millions	$ 3,815.400 Millions
Ultragenyx Pharmaceutical Inc	2.24	$ 680.000 Millions	$ 303.000 Millions
Corcept Therapeutics Inc	2.24	$ 372.152 Millions	$ 166.085 Millions
Petros Pharmaceuticals inc	2.24	$ 5.137 Millions	$ 2.293 Millions
Galectin Therapeutics Inc	2.22	$ 17.726 Millions	$ 7.967 Millions
Prf Technologies Ltd	2.22	$ 5.207 Millions	$ 2.348 Millions
Filana Therapeutics Inc	2.20	$ 95.502 Millions	$ 43.470 Millions
Mustang Bio inc	2.18	$ 17.266 Millions	$ 7.914 Millions
Dogwood Therapeutics inc	2.17	$ 6.525 Millions	$ 3.002 Millions
Omeros Corporation	2.17	$ 171.804 Millions	$ 79.208 Millions
Gossamer Bio Inc	2.16	$ 136.932 Millions	$ 63.435 Millions
Larimar Therapeutics Inc	2.11	$ 136.852 Millions	$ 64.795 Millions
Cue Biopharma Inc	2.09	$ 28.229 Millions	$ 13.494 Millions
Schrodinger Inc	2.09	$ 395.464 Millions	$ 189.136 Millions
Allarity Therapeutics Inc	2.09	$ 14.687 Millions	$ 7.030 Millions
Imunon Inc	2.08	$ 8.781 Millions	$ 4.217 Millions
Prelude Therapeutics Inc	2.05	$ 103.214 Millions	$ 50.250 Millions
Biomarin Pharmaceutical Inc	2.05	$ 1,560.609 Millions	$ 762.698 Millions
Bridgebio Pharma Inc	2.04	$ 587.482 Millions	$ 287.971 Millions
Scisparc Ltd	2.04	$ 4.591 Millions	$ 2.253 Millions
Veru Inc	2.03	$ 15.795 Millions	$ 7.785 Millions
Travere Therapeutics Inc	2.02	$ 322.796 Millions	$ 159.904 Millions

Date modified: 2026-07-07T12:11:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.